Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients
Status:
Not yet recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
Coronavirus Disease (COVID-19) is characterized by a hypercoagulable state, sometimes
difficult to be managed with heparin. Bivalirudin, a member of the direct thrombin inhibitor
drug class, offers potential advantages compared to heparin, including to its ability to
exert its effect by directly attaching to and inhibiting freely circulating and fibrin-bound
thrombin.
Investigators have therefore designed this pilot open-label randomized controlled trial to
assess if a off-label infusion of bivalirudin may reduce thrombosis, mortality, Intensive
Care Unit (ICU) length of stay and increase ventilator free days of patients admitted in ICU
for acute respiratory failure due to COVID-19, as compared to first-line treatment with
heparin.